Why Combination Therapies Hold Promise for Cystic Fibrosis
The researchers proposed that it would be successful in more than half of the people who have CF
At around the 24 week mark, the researchers were confident that the combined lumacaftor-ivacaftor therapy that they had been administering to the participants was both safe for use, and effective as treatment. The strongest results were shown within those who had two copies of F508del, which is a very specific cystic fibrosis gene mutation. The authors point out that almost half of the people who have cystic fibrosis possess this gene mutation, so finding a treatment will offer assistance to a significant number of people who are dealing with the disease.
